Rugocrixan

About Novakand Pharma

Novakand Pharma is a publicly listed, clinical-stage biotech company founded in 2018, advancing a novel platform targeting the fractalkine axis for inflammatory and oncology indications. Its strategy is to develop innovative drugs with strong IP, demonstrate human proof-of-concept, and then partner for later-stage development and commercialization via out-licensing deals. The company is currently at an inflection point, having recently evaluated strategic options after a failed reverse takeover, and is proposing a new business direction to shareholders.

Therapeutic Areas

Other Inflammatory diseases / Cancer Drugs